CORPORATE PROGRAM
Tuesday, November 12 at 6 – 8:30 PM
Admission:
This is a free event open to the public, but you must pre-register for the program. Seating is available on a first come, first served basis. For further information or assistance, please contact the Corporate Program at 212-715-1208 or email register@japansociety.org.
This is a free event open to the public, but you must pre-register for the program. Seating is available on a first come, first served basis. For further information or assistance, please contact the Corporate Program at 212-715-1208 or email register@japansociety.org.
Details in the link above and after read more.
The Global Health Innovative Technology Fund (GHIT Fund) is aimed at promoting the discovery and development of new pharmaceutical drugs, vaccines and diagnostics for infectious disease prevalent in developing countries. The first public-private partnership of its kind in Japan, the GHIT Fund was established by the government of Japan, a consortium of Japanese pharmaceutical companies and the Bill & Melinda Gates Foundation. In this program, our panelists will discuss recent successes and setbacks in global health, as well as what they regard as necessary to bring new vaccines and cures into the field. The panelists will also provide their perspectives concerning how to make public-private partnerships succeed, what lessons to take from past successes, and where the next big opportunities in global health are.
Speaker:
BT Slingsby, CEO & Executive Director, GHIT Fund
Panelists:
Kiyoshi Kurokawa, Chair of the Board & Representative Director, GHIT Fund
Peter Piot, Director, London School of Hygiene & Tropical Medicine
Melvin Spigelman, President & Chief Executive Officer, Global Alliance for TB Drug Development
Ann Veneman, Former Executive Director, UNICEF
Moderator:
Ko-Yung Tung, Senior Partner, Morrison & Foerster LLP
Agenda:
6-6:30 pm Registration
6:30-8:00 Lecture, Panel Discussion and Q&A
8-8:30 Reception